Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GJD3 antisense RNA 1 (GJD3-AS1)
- Target
- GJD3-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
GJD3 antisense RNA 1 (GJD3-AS1), also called UPLA1, is a recently characterized long non-coding RNA transcript upregulated in lung adenocarcinoma. It is predominantly expressed in the nucleus and promotes cancer cell proliferation, migration, invasion, and cell cycle progression. UPLA1 achieves these effects by activating Wnt/β-catenin signaling through interaction with desmoplakin, and is transcriptionally repressed by the factor YY1. High expression of UPLA1 is associated with poor prognosis and advanced tumor stages in lung adenocarcinoma. Currently, GJD3-AS1/UPLA1 is discussed as a biomarker more than a direct therapeutic target. There is no evidence that GJD3-AS1 encodes a protein, acts as a receptor, or is targeted by any clinically approved drugs. Its primary roles are as an oncogenic lncRNA influencing cancer pathways and as a potential prognostic biomarker.
- Other names
- UPLA1upregulation promoting LUAD-associated transcript-1
02
Mechanism of action
Not applicable for drug targeting; effects are exerted via modulation of gene expression and signaling pathways (e.g., Wnt/β-catenin activation)
03
Biological functions
Promotes cell migrationPromotes cell invasionPromotes cell proliferationAssociated with cell cycle regulationActivates Wnt/β-catenin signaling (tumor-associated signaling pathway)Regulation by transcription factor YY1 (transcriptional suppression)
04
Disease associations
Cancer (notably lung adenocarcinoma)Prognostic marker in lung adenocarcinoma
05
Safety considerations
Not applicable (as no direct therapeutic strategies or drugs are currently targeting this RNA; functional safety of modulating this lncRNA is unstudied.)
06
Biomarkers
Expression of UPLA1/GJD3-AS1 may serve as a biomarker for lung adenocarcinoma prognosis and staging (tumor, node, metastasis)
Beyond the preview
Go deeper on GJD3 antisense RNA 1 (GJD3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GJD3 antisense RNA 1 (GJD3-AS1).